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A set of 13 monoclonal antibodies (MAbs) was generated against HPV-6 L1 virus-like particles (VLPs), screened for
reactivity to HPV-6 and HPV-11 L1 VLPs by ELISA, and tested for neutralization of HPV-11 infection. Both cross-reactive
and type-specific epitopes were detected such that 4 of 13 MAbs reacted to surface conformational sites on HPV-6 L1
VLPs and the remaining 9 MAbs were cross-reactive to both HPV-6 and HPV-11 L1 VLPs. Four of the 9 cross-reactive
MAbs were able to neutralize HPV-11 infectivity, and 3 of 4 of these neutralizing MAbs (N-MAbs) identified shared surface
conformational sites. One N-MAb therefore recognized a surface linear epitope as judged by positive binding to L1 in a
Western blot assay. The neutralization status of these cross-reactive MAbs with regard to HPV-6 could not be assayed.
These results demonstrated that the closely related HPV types 6 and 11 contain both type-specific and shared neutralizing
epitopes. q 1996 Academic Press, Inc.
INTRODUCTION on the minor capsid protein L2 are limited to several
reports describing polyclonal anti-L2 sera that usually
Monoclonal antibodies (MAbs) have been developed contain low titers of neutralizing activity (Pilacinski et al.,
as specific probes to identify and characterize papillo- 1984; Christensen et al., 1991; Lin et al., 1992; Roden et
mavirus (PV) neutralizing epitopes (Christensen et al., al., 1994b; Chandrachud et al., 1995).
1990; Christensen and Kreider, 1991, 1993; Roden et al., Immunization with intact infectious PVs and PV virus-
1994b; Ludmerer et al., 1996). However, difficulties in like particles (VLPs) generate predominantly type-spe-
obtaining infectious virus stocks for infectivity assays cific antibodies with high titers of virus neutralizing activ-
have limited the analysis to several animal PVs, such as ity. The type-specificity of these polyclonal (Jenson et al.,
cottontail rabbit papillomavirus (CRPV) (Christensen and 1980; Jarrett et al., 1990; Rose et al., 1994; Roden et al.,
Kreider, 1991) and bovine papillomavirus type 1 (BPV-1) 1996) and monoclonal (Christensen et al., 1994) antibod-
(Christensen and Kreider, 1993; Roden et al., 1994b), and ies demonstrates that the conformationally dependent
one human papillomavirus (HPV) type, HPV-11 (Chris- neutralizing epitopes are highly antigenic and that cross-
tensen et al., 1990). All neutralizing MAbs (N-MAbs) gen- reactive epitopes are mostly nonneutralizing (Cowsert et
erated so far have detected highly type-specific, confor- al., 1987; Christensen et al., 1994). Detection of other
mationally dependent epitopes located on the major cap- possible neutralizing sites on PVs therefore may be diffi-
sid protein L1. The high degree of type-specificity is best cult unless this conformational, antigenically dominant,
demonstrated by HPV-11 N-MAbs in which 3/4 did not neutralizing site is absent and/or mutated.
recognize the closely related HPV-6 (Christensen et al., In this study, we have generated a panel of VLP-reac-
1994) which shares 92% amino acid sequence with HPV- tive MAbs by immunization with HPV-6 L1 VLPs. The aim
11 L1. The likelihood that linear neutralizing epitopes of the study was to determine whether cross-reactive
exist on L1 appears to be low because immunization with neutralizing epitopes (in addition to the previously de-
denatured L1 protein usually produces nonneutralizing scribed type-specific neutralizing epitopes) are located
polyclonal antibodies (Ghim et al., 1991; Kirnbauer et al., on HPV-6 and -11. MAbs showing cross-reactivity to HPV-
1992; Lin et al., 1993; Breitburd et al., 1995). In addition, 11 were tested for neutralization of HPV-11 using both
no N-MAbs targeting linear or denatured epitopes on L1 the athymic mouse xenograft system (Kreider et al., 1985;
have been described. Data defining neutralizing epitopes Christensen et al., 1990) and an HPV-11 in vitro neutral-
ization assay (Smith et al., 1993, 1995). Several catego-
ries of MAbs were generated, including MAbs that were1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (717) 531-5634. e-mail: ndc1@email.psu.edu. HPV-6 type-specific, MAbs that were cross-reactive with
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HPV-11, and MAbs that neutralized HPV-11. Both confor- added. After a 1-hr incubation, the wells were washed,
and a predetermined dilution of biotinylated MAb wasmational and linear shared neutralizing epitopes on HPV-
6 and -11 L1 were identified using the panel of MAbs. added for a further 1 hr. Alkaline-phosphatase-labeled
streptavidin (Life Technologies, Gaithersburg, MD) was
added followed by substrate to detect the amount ofMATERIALS AND METHODS
bound biotinylated MAb. Binding interference was deter-
Production and screening of monoclonal antibodies mined as a concentration-dependent reduction in the OD
values and was interpreted to indicate that the primaryMAbs reactive to surface epitopes on HPV-6 L1 VLPs
MAb had bound to the VLP at sites similar or close towere prepared as previously described (Christensen et
the epitope that was recognized by the biotinylated MAb.al., 1990, 1994). Briefly, recombinant baculovirus-induced
HPV-6 L1 VLPs were purified from infected Sf9 cells by Western blot
CsCl-banding and used as immunogen. VLPs (100 mg
MAbs reactive to denatured PV L1 antigen were testedper mouse) were mixed with complete Freund’s adjuvant
by Western blotting for reactivity to a variety of HPV L1and injected subcutaneously. Two weeks after immuniza-
preparations including HPV-6, -11, -16, and -18. Recombi-tions, mice were sacrificed, and draining lymph node and
nant baculovirus-infected Sf9 cell lysates were separatedspleens were removed for fusion with P3X63-Ag8.653
on polyacrylamide gels and transferred to Immobulon-Pmouse myeloma fusion partner cells as previously de-
membranes (Millipore, Bedford, MA) as per the manufac-scribed (Galfre et al., 1977). Hybridoma supernatants
turer’s instructions. Membranes were blocked for 1 hrwere screened against HPV-6 L1 VLPs and positive wells
in PBS containing 5% milk protein and then incubatedwere cloned and retested. A total of 13 MAbs were se-
overnight at room temperature with a 1:50 dilution oflected for further studies.
MAb supernatant. Membranes were washed in PBS andThe specificity of the MAbs was determined by direct
then developed with alkaline phosphatase-labeled anti-ELISA using intact and disrupted VLP (HPV-6, -11, -16,
mouse antisera (DAKO Corp., Carpinteria, CA) and sub-and -18) and infectious HPV-11 as previously described
strate.(Christensen et al., 1990, 1994). All VLPs were prepared
from recombinant baculoviruses and purified using pub-
HPV-11 neutralization using an athymic mouselished procedures (Kirnbauer et al., 1992; Christensen et
xenograft assayal., 1994). The Hershey strain of HPV-11 (Kreider et al.,
1985) was used for construction of the recombinant bacu- HPV-11 neutralization was determined using an
lovirus containing HPV-11 L1 (Christensen et al., 1994). athymic mouse xenograft system as previously described
Intact VLP and virus were attached to ELISA plate wells (Christensen et al., 1990). In brief, aliquots of infectious
in PBS (pH 7.0) (Cowsert et al., 1987) and disrupted VLP HPV-11 stock were incubated with a 1:10 dilution of MAb
attached after alkaline treatment and reduction (0.2 M supernatant for 1 hr at 377. Foreskin chips were added
Na2CO3 / 0.01 M dithiothreitol, pH 10.6) (Favre et al., to the virus–antibody mixture and incubated for a further
1975). 1 hr and then the chips were grafted subrenally into
athymic mice. Grafts were removed after 90 days and
Competition ELISA using selected biotinylated examined histologically for morphological changes in-
monoclonal antibodies cluding the appearance of koilocytosis and examined by
in situ hybridization for the presence of HPV-11 DNA.Selected MAbs were biotinylated as per the manufac-
Virus neutralization was determined by the presence ofturer’s instructions (Amersham, Arlington Heights, IL)
morphologically normal grafts that were in situ negative.from Protein-A (Pierce, Rockford, IL) purified ascites flu-
The monoclonal antibody H11.B2 (Christensen et al.,ids and used in ELISA binding interference tests together
1990) was used as a positive control for HPV-11 neutral-with the panel of 13 HPV-6 L1 reactive MAbs as well as
ization.the 5 HPV-11 MAbs that have been described previously
(Christensen et al., 1990). The latter 5 MAbs recognized
HPV-11 neutralization using the in vitro neutralization
conformational epitopes located on HPV-11, and 4 of 5
assay
MAbs were neutralizing (Christensen et al., 1990). All 5
of these MAbs immunoprecipitated HPV-11 L1, and 2 of Neutralization of HPV-11 by the MAbs was also tested
using the in vitro neutralization assay as previously de-5 were reactive at reduced levels to HPV-6 L1 (Hines et
al., 1995). Intact HPV-6 or HPV-11 L1 VLP antigen was scribed (Smith et al., 1993; Smith et al., 1995). This assay
provided additional information regarding the neutraliza-attached to ELISA plate wells (Christensen et al., 1994),
unattached sites were blocked with 5% milk protein in tion titer of the MAb supernatants. Replicate cultures of
the cell line HaCaT were prepared by seeding 1 1 104phosphate-buffered saline (PBS), and then 10-fold dilu-
tions (from 1:10 to 1:1000) of MAb supernatants were cells into wells of 24-well tissue culture plates. Aliquots
AID VY 8185 / 6A20$$$142 09-14-96 10:21:47 viras AP: Virology
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of infectious HPV-11 were mixed with serial dilutions of tive as the positive control MAb H11.B2. Also, MAb
H6.F62 showed weak binding to HPV-11 L1 VLPs, butMAb supernatants and incubated for 1 hr at 377 prior to
addition to the wells. Fresh medium was added at Day stronger binding to HPV-11 virus. Conversely, MAb
H6.K57 showed strong binding to HPV-11 L1 VLPs but3, and then cells were harvested at Day 6 for RNA extrac-
tion, followed by RT-PCR for detection of spliced HPV- weak binding to HPV-11 virus.
11 and cellular b-actin mRNAs as previously described
Western blotting(Smith et al., 1995). The absence of the spliced HPV-11
PCR product was interpreted to indicate MAb-induced Four MAbs reactive to denatured VLP antigen in ELISA
neutralization of HPV-11 and the presence of the b-actin were tested for reactivity to various HPV L1 proteins by
product was a control for RT-PCR and mRNA integrity. Western blotting as described under Materials and Meth-
Each dilution of MAb was tested in three separate experi- ods. MAbs H6.C6, H6.D10, and H6.I2 recognized HPV-6
ments, and neutralization titers (NT50) were determined and -11 L1 but not HPV-16 or -18 L1 (Figs. 1a, 1b, and
as the highest twofold dilution resulting in at least 50% 1c). For each of these MAbs, the major capsid protein
neutralization as previously described (Smith et al., 1995). of 55 kDa was recognized as well as numerous smaller
products that appeared to represent breakdown products
RESULTS of L1 (Jenison et al., 1988). MAb H6.E51 reacted strongly
to HPV-6 and HPV-11 L1, reacted weakly to HPV-18 L1,Production and screening of monoclonal antibodies
and did not recognize HPV-16 L1 (Fig. 1d). An HPV-16reactive to HPV-6 L1 VLPs
reactive MAb (H16.F18, (Christensen et al., 1996)) that
Hybridomas secreting antibody reactive to HPV-6 L1 was cross-reactive with HPV-18 L1 was used as a posi-
VLPs were screened by a direct ELISA using intact HPV- tive control for these latter two antigens (Fig. 1e). Some
6 L1 VLPs as described under Materials and Methods. MAbs, such as H6.I2 and H16.F18, also showed weak
A total of 13 hybridomas were selected for cloning and cross-reactivity to several insect cell proteins as shown
further studies. Of particular interest was to determine by bands in lane 1 which contained Sf9 cell lysate only.
what proportion of these MAbs showed cross-reactivity
to other HPV VLP antigens with emphasis on the closely Neutralization of HPV-11 using the athymic mouse
related HPV-11. Reactivity of the MAbs to HPV-6, -11, xenograft system
-16, and -18 L1 VLPs and to HPV-11 virus is shown in
Neutralization of HPV-11 was tested in the athymicTable 1. Of the 13 MAbs generated against HPV-6 VLPs, 4
mouse xenograft system as described under Materialswere reactive exclusively to intact HPV-6 L1 VLPs (H6.A1,
and Methods. Only the HPV-6 L1 VLP-reactive MAbs thatH6.B10.5, H6.M48, and H6.N8), and 9 were cross-reactive
also recognized HPV-11 L1 VLP and/or HPV-11 virionsto HPV-11 L1 VLPs. The cross-reactive MAbs could be
were tested for HPV-11 neutralization. Complete neutral-further subdivided into those that recognized shared con-
ization was obtained with MAb H11.B2 (positive control)formational epitopes (H6.F62, H6.H9, H6.J54, H6.K57, and
and with the cross-reactive MAb H6.L12 (data summa-H6.L12) and those that recognized shared linear epitopes
rized in Table 2). Partial or weak neutralization was ob-(H6.C6, H6.D10, H6.E51, and H6.I2). Surface linear epi-
served with the MAbs H6.I2 and H6.J54. The remainingtopes were defined by positive ELISA signals to both
MAbs showed no neutralizing activity.intact and denatured VLP, and to L1 in Western blotting.
Surface conformational epitopes were defined by posi-
Neutralization of HPV-11 using the in vitro
tive ELISA signals to intact VLP antigen only. One MAb
neutralization assay
(H6.D10) appeared to recognize an epitope that was not
surface-located because binding to intact VLP antigen Neutralization of HPV-11 using an in vitro neutraliza-
tion assay (Smith et al., 1993, 1995) demonstrated thatwas considerably reduced compared to binding to dena-
tured VLP antigen. No reactivity to distantly related HPV MAb H6.L12 was strongly neutralizing with a titer of
1:8000 (Fig. 2, and unpublished data). MAbs H6.F62,types (16 and 18) was observed, with the exception of
MAb H6.E51, which was subsequently shown to react H6.I2, and H6.J54 were weakly neutralizing with titers
ranging between 1:20 and 1:40. MAbs H6.C6, H6.E51,also with HPV-18 L1 by Western blotting (see below).
Several monoclonal antibodies generated against HPV- H6.H9, and H6.K57 (and the two cross-reactive MAbs
generated against HPV-16 L1 VLPs, H16.B20, and16 and HPV-18 L1 VLPs (Christensen et al., 1996) were
included as positive controls for these antigens. H16.D9 (Christensen et al., 1996) were nonneutralizing
at the lowest dilution of 1:10. These results were inReactivity of the MAbs to intact HPV-11 virus was not
identical to the binding obtained using intact HPV-11 L1 agreement with results from the xenograft neutraliza-
tion assay (Table 2) although the sensitivity of the inVLPs. For example, MAbs H6.H9 and H6.I2 were essen-
tially negative (and only weakly reactive at best in repeat vitro assay was greater and neutralization titers could
be determined additionally.experiments), whereas MAb H6.J54 was as strongly reac-
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To assist in interpretation of the data, a summary of the
various reactivities of the MAbs used in this study is
presented in Table 2.
a. HPV-11 neutralizing MAbs (H11.B2 and H11.H3).
Two HPV-11 N-MAbs that recognized type-specific but
not identical conformational epitopes (Ludmerer et al.,
1996) on HPV-11 were tested. For N-MAb H11.B2, seven
of eight HPV-11 N-MAbs (with the exception of the N-
MAb H6.J54) showed binding interference (Fig. 3A). The
eight N-MAbs were represented by four type-specific N-
MAbs (H11.B2, H11.F1, H11.G5, and H11.H3 (Chris-
tensen et al., 1990)), and four cross-reactive N-MAbs
(H6.F62, H6.I2, H6.J54, and H6.L12, Table 2). All five non-
neutralizing MAbs (H6.C6, H6.E51, H6.H9, H6.K57, and
H11.A3.2) showed no interference. In contrast, interfer-
FIG. 1. Western blots of reactivity of various HPV-6 L1 VLP reactive
ence of the binding of N-MAb H11.H3 was confined tomonoclonal antibodies. Cell culture supernatants of H6.C6 (A), H6.D10
only three of eight N-MAbs (H11.H3 and two cross-reac-(B), H6.I2 (C), H6.E51 (D), and H16.F18 (E) at 1:50 dilution were tested
tive N-MAbs, H6.L12 and H6.I2), and one of five nonneu-for reactivity to Sf9 insect cell lysates (lane 1), and Sf9 lysates infected
with recombinant baculoviruses producing HPV-6 L1 (lane 2), HPV-11 tralizing MAbs (H11.A3.2) (Fig. 3B).
L1 (lane 3), HPV-16 L1 (lane 4), and HPV-18 L1 (lane 5). Molecular b. HPV-11 nonneutralizing MAbs (H11.A3.2 and H6.C6).
weight markers are shown on the left. Interference of the binding of two nonneutralizing MAbs,
H11.A3.2 and H6.C6, to HPV-6 and -11 L1 VLPs by the set
Interference or blocking ELISA of MAbs was next determined. MAb H11.A3.2 was chosen
because this MAb binds to a conformationally dependentFive representative MAbs (H11.B2, H11.H3, H11.A3.2,
but nonneutralizing epitope on HPV-11 (Christensen et al.,H6.C6, and H6.M48), which included both neutralizing
1990). MAb H6.C6 was chosen because it recognizes aand nonneutralizing MAbs, were biotinylated and tested
shared surface linear epitope on both HPV-6 and HPV-11in an interference ELISA. These interference ELISAs
L1 VLPs. Interference in the binding of MAb H11.A3.2 towere designed to determine whether there was any over-
HPV-11 L1 VLPs was restricted to H11.A3.2 (positive con-lap within the epitopes recognized by type-specific HPV-
trol), three of eight HPV-11 N-MAbs, (H11.H3, H6.I2, and11 N-MAbs, cross-reactive HPV-11 N-MAbs (reactive to
H6.L12), and two nonneutralizing surface linear reactiveHPV-6 and -11), and HPV-6 type-specific MAbs. For ex-
MAbs (H6.C6 and H6.E51) (Fig. 3C).ample, a cross-reactive MAb that neutralized HPV-11
Binding interference for the nonneutralizing MAbmay have the capacity to block the binding of a type-
H6.C6 was tested using two VLP antigens, HPV-11 L1specific HPV-11 N-MAb as well as a type-specific HPV-
VLPs (Fig. 3D) and HPV-6 L1 VLPs (Fig. 3E). Only two6-reactive MAb, thereby providing indirect evidence that
cross-reactive N-MAbs (H6.I2 and H6.L12) and two non-the latter MAb has the potential to neutralize HPV-6 infec-
neutralizing MAbs (H6.E51 and H11.A3.2) blocked thetivity. This result would be possible if the type-specific
binding of MAb H6.C6.conformational neutralizing site contained additional epi-
c. HPV-6 surface conformational reactive MAb (H6.M48).topes that were either cross-reactive or linear in nature.
One conformationally dependent type-specific MAb thatMAbs H11.B2 and H11.H3 recognized a conforma-
was reactive only to intact HPV-6 L1 VLP was chosentional neutralizing site on HPV-11 (Christensen et al.,
to be tested for binding interference. The neutralization1990), but did not recognize identical amino acid resi-
status of this MAb (H6.M48) could not be determined.dues (Ludmerer et al., 1996). MAb H11.A3.2 recognized
Cross-reactive N-MAbs H6.I2 and H6.L12, cross-reactivea nonneutralizing conformational epitope on HPV-11
nonneutralizing MAbs H6.C6 and H6.E51, and three of(Christensen et al., 1990). MAb H6.M48 recognized a
the four HPV-6 L1 VLP-specific MAbs showed bindingconformational epitope present only on HPV-6 L1 VLP
interference (Fig. 3F). These latter MAbs included(Christensen et al., 1995), and MAb H6.C6 recognized a
H6.M48 (positive control), H6.A1, and H6.B10.5 (interfer-
shared surface linear epitope on HPV-6 and HPV-11 L1
ence was stronger using H6.B10.5 ascites). Only one
VLPs and was nonneutralizing for HPV-11 (Table 2).
of four HPV-6 L1 VLP-reactive MAb (H6.N8) and the
The results of the MAb interference ELISAs are pre- remaining cross-reactive MAbs (H6.H9 and H6.K57)
sented in Fig. 3. The data demonstrated that there was showed no interference.
a complex level of interference interactions between
DISCUSSIONmany of the MAbs. The data in the graphs are included
under Results for completeness and as a reference for We have generated a panel of MAbs reactive to HPV-
6 L1 VLPs and screened these MAbs additionally forfuture studies on epitope characterization of these MAbs.
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of epitopes on HPV-6 L1 VLPs that induce antibodies
that can neutralize HPV-11, however, would be strong
circumstantial evidence that these MAbs will also neu-
tralize HPV-6 infectivity. Thirteen MAbs were generated
of which 4 were type-specific for HPV-6 L1 VLPs and the
remaining 9 were cross-reactive with HPV-11. HPV-11
neutralization assays determined that 4 of 9 cross-reac-
tive MAbs were virus neutralizing although 3 of 4 were
only weakly neutralizing. One of these weak N-MAbs
(H6.I2) was found to bind to denatured L1 by both West-
ern blotting and ELISA, suggesting that this MAb identi-
fied a surface linear neutralizing site on HPV-11 L1. Two
additional clones from this hybridoma line were also IgM
isotype, Western blot positive, and virus neutralizing
(data not shown).
FIG. 2. RT-PCR analysis of HPV-11 neutralization by HPV-6 cross- Two HPV-11 neutralization assays, the xenograft sys-
reactive monoclonal antibodies. Ethidium-agarose gel electrophoresis
tem (Christensen et al., 1990) and the in vitro systemof RT-PCR products. The positions of the 628 bp (HPV-11 mRNA) and
(Smith et al., 1993, 1995) were used to screen the setthe 429 bp (b-actin mRNA) amplimers are indicated. (Top) Lanes A–
E, H6.L12 (1:10, 1:30, 1:270, 1:720, 1:2160); lanes F–K, H6.J54 (1:5, 1:10, of cross-reactive MAbs. Additional information as to the
1:20, 1:40, 1:80, 1:160); lanes L – N, H6.H9, H16.B20, and H16.D9 (all at neutralization titer of MAb supernatants was provided
1:10); lane O, positive control xenograft condyloma mRNA, and lane P, using the in vitro neutralization assay, and the data dem-
Fx174 DNA HaeIII digest markers. (Bottom) Lanes A–F, H6.I2 (1:10,
onstrated that 3 of 4 of the new N-MAbs were weakly1:20, 1:40, 1:80, 1:160, 1:320); lanes G–L, H6.F62 (1:10, 1:20, 1:40, 1:80,
neutralizing. Low concentrations of antibody in the super-1:160, 1:320); lanes M–O, H6.K57, H6.C6, and H6.E51 (all at 1:10); lane
P, HaeIII digest markers. natants (Table 1) may be one explanation for this weak
neutralizing activity. However, one of the weak N-MAbs
(H6.J54) was weakly neutralizing despite the supernatant
cross-reactivity to HPV-11 by ELISA and for neutralization containing a relatively high titer of antibody as deter-
of HPV-11 infectivity. Earlier work with a set of HPV-11 mined by ELISA. These data suggest that the N-MAb
N-MAbs (Christensen et al., 1990, 1994) suggested that H6.J54 showed some unknown inefficiency of neutraliza-
neutralizing epitopes were predominantly type-specific,
conformational, and highly antigenic. The major differ-
ence in protocol for MAb development in this study was
the use of high concentrations of antigen (HPV-6 L1 VLP)
in a single immunization. Previously, we immunized mice
multiple times with low concentrations of infectious HPV-
11 virions (Christensen et al., 1990). The methods used
in this study therefore should increase the frequency of
hybridomas secreting antibodies of reduced affinities
and of the IgM subclass because only one immunization
was used prior to hybridoma construction.
The rationale for using HPV-6 L1 VLP antigen in this
study was to determine whether cross-reactive neutraliz-
ing sites were also present on HPV-11 by using a source
of antigen (HPV-6 L1 VLPs) that does not contain the
highly antigenic, type-specific, conformational neutraliz-
ing site that is present on HPV-11 (i.e., using HPV-11 L1
FIG. 3. Interference ELISA using biotinylated MAbs, H11.B2 and HPV-VLPs would have produced a predominant response to
11 L1 VLP antigen (A), H11.H3 and HPV-11 L1 VLP antigen (B), H11.A3.2type-specific conformational neutralizing epitopes on
and HPV-11 L1 VLP antigen (C), H6.C6 and HPV-11 L1 VLP antigen
HPV-11 as previously shown (Christensen et al., 1990)). (D), H6.C6 and HPV-6 L1 VLP antigen (E), and H6.M48 and HPV-6 L1
One requirement for defining cross-reactive neutralizing VLP antigen (F). Dilutions of unlabeled MAbs, H11.A3.2 (n), H11.B2
(j), H11.F1 (v), H11.H3 (l), H6.A1 ( ), H6.B10.5 (b), H6.C6 (s),epitopes is the assumption that a MAb generated against
H6.E51 (m), H6.F62 (,), H6.I2 (x), H6.J54 (h), H6.L12 (L), H6.M48 (.),HPV-6 L1 VLPs that also recognizes and neutralizes HPV-
H6.N8 (c), and CRPV-1A (l) were added to antigen-coated ELISA plate
11 infectivity has the capacity to neutralize HPV-6 infec- wells, followed, after washing, with biotinylated MAbs. Mean OD of the
tion. This assumption is necessary because neutraliza- binding of biotinylated MAbs to antigen in the absence of unlabeled
MAbs (s) is shown on the left.tion of HPV-6 cannot currently be tested. The presence
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tion or that neutralization of HPV-11 occurred by a mech- An overall assessment of the ELISA blocking data sug-
gests that both N-MAbs and nonneutralizing MAbsanism that is different when compared to the majority of
the previously described N-MAbs which were strongly showed various degrees of epitope overlap. Taken to-
gether, the interference ELISA data suggested that it wasneutralizing (Christensen et al., 1990; Christensen and
Kreider, 1991; Roden et al., 1994b). It was interesting to not possible to separate type-specific N-MAbs from the
cross-reactive N-MAbs. There are several factors thatnote that all three of the IgM MAbs (H6.F62, H6.I2, and
H6.L12) were neutralizing. The polyvalency and size of may contribute to the apparent complexity of the data.
These include antibody affinity, antibody size, the smallthe IgM antibody molecules may have provided an in-
creased capacity for neutralization although only one of size of the papillomavirus capsid, and possible structural
alterations of adjacent epitopes following binding by thethese IgM N-MAbs (H6.L12) was strongly neutralizing.
Earlier studies using rabbit polyclonal antisera gener- primary MAb. For example, two IgM N-MAbs (H6.I2 and
H6.L12) appeared to prevent subsequent binding of allated against HPV-6 and HPV-11 L1 VLPs demonstrated
that HPV-6 L1 VLPs induced only low titers of HPV-11 MAbs, including those that were neutralizing and those
that were not. Different MAb affinities may also influenceneutralizing antibodies, whereas HPV-11 L1 VLPs in-
duced high neutralization titers (Christensen et al., 1994). the level of interference. A high-affinity (and biotinylated)
MAb may displace unlabeled MAbs of low affinity fromA similar difference between polyclonal antisera raised
against HPV-6 and -11 L1 VLPs has been observed using the VLP surface, leading to an interpretation that these
two MAbs were recognizing nonoverlapping epitopes.antibody-mediated prevention of VLP-induced agglutina-
tion of mouse red blood cells (RBC) (Roden et al., 1996). Differences in affinity may explain why N-MAb H11.H3
blocked subsequent binding of biotinylated N-MAbThe above studies with the panel of HPV-6 L1 VLP-reac-
tive MAbs indicate that cross-reactive neutralizing sites H11.B2 to HPV-11 L1 VLP antigen, but H11.B2 did not
appear to block the binding of biotinylated H11.H3 tobetween HPV-6 and HPV-11 do exist. Only one of the
four cross-reactive N-MAbs (H6.L12) was strongly neu- HPV-11 L1 VLP antigen (Figs. 3A and 3B). Structural
changes to antigen upon interaction with antibodies aretralizing for HPV-11, however, and three of four cross-
reactive N-MAbs were of the IgM subclass. If cross-reac- another mechanism that can influence the subsequent
binding to antigen of a second MAb. Structural changestive N-MAbs are predominantly IgM, then the titers of
such antibodies would be low in polyclonal antisera gen- following antibody binding have been discussed theoreti-
cally (Monod et al., 1965) and demonstrated experimen-erated after several booster immunizations with VLP anti-
gen (Christensen et al., 1994; Roden et al., 1996). These tally in several systems (Dean and Schechter, 1979; Ber-
zofsky, 1985; Iverson and Lerner, 1989; Stanfield et al.,studies again emphasize the strong antigenicity of the
conformational, type-specific neutralizing epitopes of 1990; Rini et al., 1992) including viruses (Clegg et al.,
1983; McCullough et al., 1987).papillomaviruses and suggest also that some of the HPV-
6 L1 VLP type-specific conformationally reactive MAbs In summary, a panel of 13 HPV-6 L1 VLP reactive MAbs
was generated and 9 of these MAbs were cross-reactive(H6.A1, H6.B10.5, H6.M48, and H6.N8) may have the ca-
pacity to strongly neutralize HPV-6 infectivity. with HPV-11 L1 VLP by ELISA. Neutralization of HPV-11
infection demonstrated that 4 of 9 cross-reactive MAbsAlthough an assay to measure HPV-6 neutralization is
currently unavailable, there are several in vitro assays were neutralizing, and the expectation is that these MAbs
could also neutralize HPV-6 infectivity. Cross-reactivethat have been developed that may be used as possible
surrogates for PV neutralization. These assays include conformational and linear neutralizing epitopes were
identified. The possibility that type-specific and cross-antibody-mediated blocking of the binding of PV VLPs to
the surface of various target cells (Roden et al., 1994a,b; reactive neutralizing epitopes represented separate epi-
topes on the capsid surface could not be accurately de-Mu¨ller et al., 1995; Volpers et al., 1995) and antibody-
mediated blocking of PV VLP-induced agglutination of termined because of the complexity of the binding inter-
actions between these MAbs. To date, neutralizing MAbsmouse RBC (Roden et al., 1995). However, examples of
PV N-MAbs have been found that did not prevent PV have detected only type-specific conformational neu-
tralizing epitopes. The current studies demonstrated thatVLPs from binding to cell surfaces (Roden et al., 1994b),
and several HPV-11 and CRPV N-MAbs (Christensen et additional neutralizing epitopes exist which retain limited
cross-reactivity. In addition, one linear neutralizing epi-al., 1990; Christensen and Kreider, 1991) did not prevent
HPV-11 and CRPV VLP-induced agglutination of mouse tope on the major capsid protein was identified but not
mapped. These MAbs may be useful probes for analyzingRBC respectively (Roden et al., 1996). These latter obser-
vations indicate that our understanding of the various surface epitopes on HPV-6 and HPV-11 and for mapping
neutralization sites that may be secondary to the antigen-mechanisms by which antibodies mediate neutralization
of PVs is limited and that a virus neutralization assay ically dominant type-specific conformational site pre-
viously characterized (Ludmerer et al., 1996). Identifica-is still required to definitively assess the neutralization
potential of a PV-reactive MAb. tion of cross-reactive neutralizing epitopes on PV VLP
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Comparison of neutralization of BPV-1 infection of C127 cells andantigens may have important implications for the design
bovine fetal skin xenografts. Int. J. Cancer 49, 285–289.of PV subunit vaccine strategies.
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